drugset / Trial / NCT00004497

Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension

NCT00004497

Phase 3 Completed United Therapeutics
RandomizedDouble-blindTreatment

Summary

OBJECTIVES: I. Determine the safety and efficacy of UT-15 in patients with severe symptomatic primary pulmonary hypertension.

Timeline

Start
1998-10
Primary completion
Completion
2000-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified Subcutaneous